13 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol (RESOLVE)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
"Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CV ...
Voir le projet
14
Participants partenaires
TERMINÉ
Pre-normative research on resistance to mechanical impact of composite overwrapped pressure vessels (HYPACTOR)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2017,
"Hydrogen is expected to be a highly valuable energy carrier for the 21st century as it should participate in answering main societal and economical concerns. However, in order to enable its extensive use as an energy vector, it is of primary importance to ensure its societal acceptance and thus its safety in use. To this aim, hydrogen storage and transportation must be secured. In particular toda ...
Voir le projet
7
Participants partenaires
TERMINÉ
A common European approach to the regulatory testing of nanomaterials (NANOREG)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issues. While toxicity data is continuously becoming available, the relevance to regulators is often unclear or unproven. The shrinking time to market of new MNM drives the need for urgent action by regulators. NANoREG is the first FP7 project to deliver the answe ...
Voir le projet
73
Participants partenaires
TERMINÉ
SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING (AGEDBRAINSYSBIO)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,
In spite of valuable approaches applied to get a broad understanding of genetic, epidemiologic and molecular and system-level biological principles of human aging, cognitive decline remains as one of the greatest health challenges of the old age, with nearly 50% of adults over 85 afflicted of Alzheimer’s disease. Furthermore, drug development has not performed as expected in clinical trials, at le ...
Voir le projet
15
Participants partenaires
TERMINÉ
Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)
Date du début: 1 oct. 2011, Date de fin: 31 mars 2016,
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain.Based on harmonised and standardised European population cohorts we have built significant research collabo ...
Voir le projet
31
Participants partenaires
TERMINÉ
The targeted development of a new generation Vaccine for Schistosomiasis (TheSchistoVac)
Date du début: 1 févr. 2010, Date de fin: 31 juil. 2014,
The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or glycans of the vulnerable skin stage schistosomula, making it safe and effective. The life stage-specific vaccine target selection strategy is based on state-of-the-art schistosomal transcriptomics and glycomics technologies and data, and unique serum and sample ...
Voir le projet
14
Participants partenaires
TERMINÉ
Pan-European network for the study and clinical management of drug resistant tuberculosis (TB PAN-NET)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2014,
"This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB) facing the EU. The objective will be attained through the establishment of a European consortium of expert partners with extensive experience in the conduct of basic and clinical research relating to MDR-TB, TB control and epidemiology. This Consortium will ...
Voir le projet
32
Participants partenaires
TERMINÉ
Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)
Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,
"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet
39
Participants partenaires
TERMINÉ
A Novel Filtration Technology Targeted at Enhancing the European Healthcare System´s Efforts in Restraining the Spread of the Hospital Infection (HAIFREE)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2012,
"At healthcare facilities, there is a strong demand for a new advanced air cleaning technology to prevent infectious diseases such as severe acute respiratory syndrome (SARS) and Hospital Acquired Infections (HAI). The system would avoid the high costs related to healthcare and legal matters which increase every year and are a burden to the fixed costs of maintaining sanitary systems in Europe and ...
Voir le projet
8
Participants partenaires
TERMINÉ
Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis (HOMITB)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,
"Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt clinical disease, do so within two years of primary infection. The remaining half of the TB patients, develop clinical disease later, owing to “reactivation” of pulmonary TB. Of importance, it is not understood why only 10% infected individuals develop activ ...
Voir le projet
9
Participants partenaires
TERMINÉ
Development and pre-operational validation of upgraded GMES Marine Core Services and capabilities (MyOcean)
Date du début: 1 janv. 2009, Date de fin: 31 mars 2012,
MyOcean is THE PROJECT to set up infrastructures, services and resources to prepare the operational deployment of first Marine Core Services. My Ocean answers to the topic SPA.2007.1.1.01 - development of upgraded capabilities for existing GMES fast-track services and related (pre)operational services. MyOcean is proposed by a consortium of 67 partners spread in maritime countries: - federated aro ...
Voir le projet
60
Participants partenaires
TERMINÉ
Targeting OBesity-driven Inflammation (TOBI)
Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,
"The TOBI project aims to analyse mechanisms provoking adipokine-mediated crosstalk and an inflammatory drift in obese patients. It will be the remit of this project to develop novel strategies to reduce or reverse major adipokine-mediated adverse interactions in peripheral tissues and by periorganic adipose tissue, namely insulin resistance and vascular dysfunction, respectively. Special attentio ...
Voir le projet
10
Participants partenaires
TERMINÉ
The role of p16INK4a in the development of obesity and insulin resistance (P16 and metabolism)
Date du début: 2 mars 2009, Date de fin: 1 mars 2011,
Genome-wide association studies have linked the CDKN2A locus to an increased risk of Type 2 Diabetes (T2D), which is mostly accompanied by insulin resistance (IR) and obesity. The CDKN2A locus encodes p16INK4a, a tumor suppressor. p16INK4a is an inhibitor of cyclin-dependent kinases, which regulate the cell cycle. Recent studies have shown a link between p16INK4a and the control of inflammation. T ...
Voir le projet